 WESTLAKE VILLAGE, Calif., Oct. 4, 2021 PRNewswire -- MannKind Corporation Nasdaq: MNKD, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today the enrollment of the first pediatric patient in the INHALE-1 study. 